Table 2
Trial | Arrival Mh culture | 3‐week Mh Culture | 10‐week Mh Culture |
---|---|---|---|
Fall 2019 | 15.5% | 39.0% | 4.8% |
Meta | 26.2% | 48.8% | 4.8% |
No meta | 4.8% | 29.3% | 4.8% |
Fall 2020 | 20.2% | 55.6% | 9.5% |
Meta | 19.0% | 58.5% | 14.3% |
No meta | 21.4% | 52.5% | 4.8% |
Spring 2021 | 8.4% | 28.9% | 20.0% |
Meta | 4.8% | 37.5% | 23.7% |
No meta | 11.9% | 19.4% | 15.6% |
Fall 2021 | 42.9% | 48.2% | 12.3% |
Meta | 45.2% | 42.9% | 14.3% |
No meta | 40.5% | 53.7% | 10.2% |
All trials | 21.8% | 43.2% | 11.3% |
Meta | 23.8% | 46.9% | 14.0% |
No meta | 19.8% | 39.2% | 8.4% |
M. haemolytica isolation rate.